Medicare Prescription Drug Benefit and Medicare Advantage FIinal Regulations
Client Alert | 1 min read | 03.03.05
Introduction
Crowell & Moring LLP's HealthCare Group is pleased to provide our clients and visitors to our Website with the following analysis of the Medicare Prescription Drug Benefit and Medicare Advantage final regulations. Rather than attempt to summarize 548 Federal Register pages of preambles and regulations, our analysis focuses on the changes between the proposed and final regulations and the commentary that explains those changes. We have also tried to note the many instances in which CMS promised later guidance to address matters not covered in the final rules.
Please click on the links below to view Crowell & Moring's analysis.
The above summaries are not a substitute, of course, for a careful review of the regulations and commentary themselves. To assist your further review, here are links to the Federal Register1 version of the regulations:
Title I (Prescription Drug Plan) Final Regulations
Title II (Medicare Advantage) Final Regulations
Equally obviously, Crowell & Moring's HealthCare Group would be happy to help you with the interpretation and application of these regulations. Feel free to call your regular Crowell & Moring contact or any of the authors listed below.
Kenneth M. Bruntel
Editor
1. Unless otherwise indicated all “FR” page references are to Volume 70 of the January 28, 2005 Federal Register. Also unless otherwise noted, cites to Code of Federal Regulations sections ( e.g. , § 423.1) are to 42 CFR.
Insights
Client Alert | 4 min read | 02.20.26
SCOTUS Holds IEEPA Tariffs Unlawful
On February 20, 2026, the Supreme Court issued a pivotal ruling in Trump v. V.O.S. Selections, negating the President’s ability to impose tariffs under IEEPA. The case stemmed from President Trump’s invocation of IEEPA to levy tariffs on imports from Canada, Mexico, China, and other countries, citing national emergencies. Challengers argued—and the Court agreed—that IEEPA does not delegate tariff authority to the President. The power to tariff is vested in Congress by the Constitution and cannot be delegated to the President absent express authority from Congress.
Client Alert | 7 min read | 02.20.26
Section 5949 Proposed Rule Puts the FAR Council's Chips on the Table
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs
Client Alert | 4 min read | 02.19.26
Proposed NY Legislation May Mean Potential Criminal Charges for Unlicensed Crypto Firms
